- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00775359
Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions
Comparative, Randomized, Single-Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Abbott (TriCor®) 160 mg Fenofibrate Tablets in Healthy Adult Volunteers Under Fed Conditions
Study Overview
Detailed Description
This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult male and female volunteers A total of 23 subjects (16 males and 7 females) completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 24-hour blood draw. Subjects returned for all subsequent blood draws. Doses were separated by a washout period of 10 days.
Of the 24 healthy adult male and female volunteers enrolled in the study, 23 subjects (16 males and 7 females) completed the clinical phase of the study. Subject No. 10 failed to return for Period 2 check-in.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85044
- MDS Pharma Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject candidates must fulfill the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- Healthy adult male and female volunteers, 18-55 years of age;
- Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983);
- Medically healthy subjects with no clinically abnormal laboratories and ECGs, as deemed by the principal investigator;
Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable birth control methods:
- Surgically sterile (tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum. Proof is required for the hysterectomy and oophorectomy;
- IUD in place for at least 3 months;
- Barrier methods with spermicide (condom, diaphragm) for at least 14 days prior to the start of the study and throughout the study;
- Surgical sterilization of the partner (vasectomy for 6 months minimum);
- Hormonal contraceptives for at least 3 months prior to the start of the study. Other birth control methods may be deemed acceptable.
- Postmenopausal women with amenorrhea for at least 2 years;
- Voluntary consent to participate in the study.
Exclusion Criteria:
Subject candidates must not be enrolled in the study if they meet any of the following criteria:
- History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
In addition, history or presence of:
- alcoholism or drug abuse within the past 2 years;
- hypersensitivity or idiosyncratic reaction to fenofibrate or other lipid regulating agents.
- Female subjects who are pregnant or lactating.
- Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dosing.
- Subjects who have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 30 days prior to the study.
- Subjects who have made a plasma donation within 7 days prior to the study.
- Subjects who have participated in another clinical trial within 30 days prior to the first dose.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Fenofibrate 160mg Tablets of Ranbaxy
|
|
Active Comparator: 2
TriCor® 160 mg Fenofibrate Tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bioequivalence
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AA01824
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Fenofibrate 160 mg tablets
-
Ranbaxy Laboratories LimitedCompleted
-
Intermountain Health Care, Inc.Merck Sharp & Dohme LLC; AbbottCompletedType II Diabetes Mellitus | Mixed DyslipidemiaUnited States
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Solvay PharmaceuticalsCompletedHealthy VolunteersUnited Kingdom
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedDiabetes Complications | Type II Diabetes MellitusUnited States
-
Chong Kun Dang PharmaceuticalUnknownMixed HyperlipidemiaKorea, Republic of
-
Genencell Co. Ltd.Recruiting
-
Daiichi Sankyo, Inc.CompletedHypercholesterolemia | Hyperlipidemia, Familial CombinedUnited States
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States